The National Cancer Institute is launching a major clinical trial in which it will play matchmaker between 1,000 advanced cancer patients and the growing cadre of drugs that can target tumors by their genetic mutations, not just where they occur in the body. At least 10 pharmaceutical companies will provide a total of more than 20 treatments to be tested—all under the structure of a single study, according to The Wall Street Journal. The drugs will include those already on the market, as well as in development.